Business Wire

MD-IONQ

22.7.2024 14:01:26 CEST | Business Wire | Press release

Share
IonQ Unveils Accelerated Roadmap and New Technical Milestones to Propel Commercial Quantum Advantage Forward

IonQ (NYSE: IONQ), a leader in the quantum computing industry, recently unveiled expanded and accelerated 2025 technical milestones during an exclusive webinar hosted by CEO Peter Chapman, SVP of Engineering & Technology Dean Kassmann, and CMO Margaret Arakawa. IonQ established why it is the only quantum computing company designing and building best-in-class quantum computers that meet the requirements of performance, scalability, and enterprise-grade solutions that are critical for delivering unparalleled commercial advantage to customers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240722272052/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

IonQ's three-pillar technology strategy to accelerate commercial advantage. (Graphic: Business Wire)

“It is imperative that we address performance, scale, and enterprise-grade quantum solutions simultaneously to achieve commercial advantage,” said Peter Chapman, President and CEO of IonQ. “Working to operationalize all three commercial advantage pillars is an industry-first that sets us apart. While other companies may hyperfocus on a single dimension, we focus on the complete picture, to ensure our quantum computing solutions are best-in-class and provide incomparable value to our customers.”

“Based on market demand, we’ve embarked on a path that no other commercial quantum computing company is taking, and we are committed to accelerating our quantum computing strategy as demonstrated by these ambitious goals,” said Dean Kassmann, SVP of Engineering & Technology at IonQ. “Our unique approach combines high performance single core operation, multi-core parallelism, modularity, photonic interconnects, novel technology, and systems engineering to deliver highly performant, scalable, and enterprise-grade quantum computers that drive meaningful advancements across various industries.”

Performance: Driving Efficiency and Unparalleled Flexibility

Performance improvements are core to IonQ’s technical roadmap, and the path toward meeting IonQ’s aggressive performance targets is clear. Native gate fidelity, architectural design decisions, and error correction will serve as levers to achieve these goals. IonQ is driving to improve native two-qubit gate performance to greater than three 9’s (>99.9%) in 2025, with further gains – fueled by the move to barium qubits – expected the following year. Performance improvements are also expected from highly efficient realizations of quantum algorithms that are enabled by IonQ’s low-shuttling, high-connectivity architectures. Lastly, the combination of high native gate fidelity and high connectivity provides unparalleled flexibility for implementing error correction and reducing time to solution. With this updated quantum architecture, IonQ expects to reach five 9’s (99.999%) in logical two-qubit gate fidelity by the end of 2025, opening up new application performance capabilities.

Scale: Architecture that Enables Expansive Growth

IonQ is pursuing scale in tandem with performance. IonQ’s north star is scalability at high performance, and modularity is a critical component of this strategy. IonQ’s approach to scale relies on making engineering and architectural decisions that support performance at large qubit counts. In addition, IonQ’s strategy for scaling takes advantage of multicore operation and photonically interconnected systems. Connecting multiple QPUs and quantum systems with photonic interconnects will enable IonQ to target 1000s of physical qubits in the future. These higher qubit counts will unlock new problem spaces and enable developers and researchers to tackle increasingly complex problems.

Enterprise-Grade: Meeting Real-World Needs

IonQ’s enterprise-grade approach readies its quantum systems for deployment across various sectors, focusing on manufacturability, deployability, and customer applications at scale. IonQ has already formed successful partnerships with organizations like the Naval Research Laboratory (NRL), Airbus, and Deutsches Elektronen-Synchrotron (DESY) – an internationally renowned center of fundamental research – as they focus on optimization problems and quantum chemistry and other important real-world applications. Additionally, IonQ is exploring a growing number of quantum algorithms across fields such as AI, financial services, and cybersecurity, reinforcing its commitment to real-world quantum technology applications.

Currently, IonQ operates two quantum data centers—one at its headquarters in College Park, Maryland, and another in Seattle, Washington, which the company opened earlier this year. Later this year, IonQ will expand its footprint by bringing its quantum data center in Basel, Switzerland, online. All of these locations are dedicated to supporting the needs of IonQ’s customers.

This momentum underscores IonQ's leadership in the quantum computing industry and robust industry demand. IonQ's enterprise strategy and expanding infrastructure highlight its dedication to unlocking commercial advantage by collaborating with industry leaders and making cutting-edge, well-balanced, quantum technology available ahead of schedule.

To learn more about IonQ and its latest system news and business developments, visit https://ionq.com/.

About IonQ

IonQ, Inc. is a leader in quantum computing that delivers high-performance systems capable of solving the world’s largest and most complex commercial and research use cases. IonQ’s current generation quantum computer, IonQ Forte, is the latest in a line of cutting-edge systems, boasting 36 algorithmic qubits. The company’s innovative technology and rapid growth were recognized in Fast Company’s 2023 Next Big Things in Tech List and Deloitte’s 2023 Technology Fast 500™ List, respectively. Available through all major cloud providers, IonQ is making quantum computing more accessible and impactful than ever before. Learn more at IonQ.com.

IonQ Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Some of the forward-looking statements can be identified by the use of forward-looking words. Statements that are not historical in nature, including the words “accelerate,” “advance,” “dedicate,” “deploy,” “drive,” “enable,” “expand,” “expect,” “improve,” “will,” and other similar expressions are intended to identify forward-looking statements. These statements include those related to the company’s technology driving commercial advantage in the future, the ability for third parties to implement IonQ’s offerings to increase their quantum computing capabilities, the effect of increased availability of customer support functions and enterprise-grade solutions, IonQ’s quantum computing capabilities and plans, access to IonQ’s quantum computers, increases in algorithmic qubit achievement, and the scalability, performance, and reliability of IonQ’s quantum computing offerings. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: changes in the competitive industries in which IonQ operates, including development of competing technologies; changes in laws and regulations affecting IonQ’s business; IonQ’s ability to implement its business plans, forecasts and other expectations, identify and realize partnerships and opportunities, and to engage new and existing customers. You should carefully consider the foregoing factors and the other risks and uncertainties disclosed in the Company’s filings, including but not limited to those described in the “Risk Factors” section of IonQ’s most recent Quarterly Report on Form 10-Q and other documents filed by IonQ from time to time with the Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and IonQ assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. IonQ does not give any assurance that it will achieve its expectations.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240722272052/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Investor Supporting Japan’s Entertainment Industry, Yoshihiro Shimamura, to Visit France Workshop to be Held During the Cannes Film Festival28.4.2026 04:00:00 CEST | Press release

Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of Hankyu Hanshin Holdings, Inc.—a major Japanese entertainment conglomerate known for producing content enjoyed across generations—and became a major shareholder (as of March 25, 2026). Through such investments, the company aims to support the global expansion of Japanese entertainment while exploring synergies with its own interna

Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release

Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye